An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials
Related Articles
Reconsidering the revised amyotrophic lateral sclerosis functional rating scale for ALS clinical trials
Introduction Clinical trials in amyotrophic lateral sclerosis (ALS) aim to identify treatments that can slow functional decline or prolong survival time. In the absence of…
Metabolic brain changes across different levels of cognitive impairment in ALS: a 18F-FDG-PET study
Objective To identify the metabolic changes related to the various levels of cognitive deficits in amyotrophic lateral sclerosis (ALS) using 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET)…
Value of systematic genetic screening of patients with amyotrophic lateral sclerosis
Objective The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis (ALS) is uncertain. Our aim was to determine whether routine targeted sequencing of…
Publication Rate and Consistency of Registered Trials of Motor-Based Stroke Rehabilitation
Objective To determine the publication rate of motor-rehabilitation trials poststroke and the consistency between registry records and their corresponding main publications in trial design, primary…
Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner
Objective To determine whether neutrophils contribute to amyotrophic lateral sclerosis (ALS) progression, we tested the association of baseline neutrophil count on ALS survival, whether the…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses